Spots Global Cancer Trial Database for Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC

Official Title: Chemoradiation Plus tisLelizumAb for Conversion Therapy of Locally Nonresectable ESCC

Study ID: NCT05394415

Conditions

Esophageal Squamous Cell Carcinoma

Tislelizumab

Chemoradiation

Interventions

Study Description

Brief Summary: This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.

Detailed Description: The success of PD-1 antibody immunotherapy has brought about tremendous changes in clinical practice for treating patients with ESCC. Many patients with ESCC were not resectable at first presentation because of locally advanced disease in the primary site and/or in lymph nodes. The primary intention of our study was to evaluate the feasibility and efficacy of combining tislelizumab and chemoradiation for conversion therapy for these patients. The enrolled patients in this study should be with pathologically proved ESCC staged IIIb-IVa according to the 8th edition of UICC/AJCC TNM stage classification. This is a single institution and single-arm phase I/II study, the estimated enrollment was 30 participants.